Evidence map›Paper›PMID 40760500›Full record

ReviewStem cell research & therapy2025

Stem cell-based therapeutic strategies for down syndrome and Alzheimer's disease.

Osama Hamadelseed, Thomas Skutella

Abstract readReview
In one paragraph

Review in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Osama HamadelseedDepartment of Neuroanatomy, Institute of Anatomy and Cell Biology, University of Heidelberg, Heidelberg, Germany. Osama.hamadelseed@uni-heidelberg.de.ORCID http://orcid.org/0000-0003-3273-7368
Thomas SkutellaDepartment of Neuroanatomy, Institute of Anatomy and Cell Biology, University of Heidelberg, Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDown syndrome (DS) and Alzheimer's disease (AD) are two distinct yet interconnected neurological conditions that share overlapping pathological features, including amyloid-beta plaque accumulation, neuroinflammation, and progressive neurodegeneration. Individuals with DS are at increased risk of developing AD-like dementia owing to the overexpression of the amyloid precursor protein-encoding gene on chromosome 21. Despite significant research efforts, effective disease-modifying treatments remain unavailable for both conditions, necessitating the exploration of novel therapeutic approaches.

methodsWe analyzed and synthesized the existing literature on stem cell therapy as a treatment for DS and AD. We conducted a comprehensive search of PubMed, Google Scholar, and Web of Science databases, focusing on recent, high-quality, and peer-reviewed studies on stem cell therapy in DS and AD.

resultsThe findings indicate that stem cell therapy represents a promising therapeutic approach for both conditions. Preclinical trials using neural, mesenchymal, and induced pluripotent stem cells have shown their potential to mitigate disease pathology, restore neuronal function, modulate neuroinflammation, enhance neurogenesis, and improve cognitive performance in DS and AD models; these findings suggest the viability of stem cell-based interventions as a disease-modifying strategy. However, despite promising findings, the efficacy and safety of these approaches require further validation through well-designed human clinical trials before clinical translation. Furthermore, AD research in stem cell therapy is currently more advanced than DS research, with a greater number of preclinical and early clinical investigations. In fact, people with DS have been previously excluded from clinical trials.

conclusionsWhile both DS and AD share common neurodegenerative mechanisms and are potential candidates for stem cell therapeutic approaches, the therapeutic focus varies. This study underscores the potential of stem cell therapy as a novel disease-modifying approach for both conditions while emphasizing the need for further research to refine therapeutic protocols, address ethical and safety concerns, and evaluate the feasibility of translating these therapies into clinical practice.

Indexed as

Alzheimer DiseaseDown SyndromeStem Cell TransplantationAnimalsHumansAlzheimer’s diseaseDementiaDown syndromeNeurodegenerative diseasesStem cell therapyTrisomy 21

Identifiers

PMID40760500
PMCPMC12323096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.